Adam Lynch
- Partner
- Corporate
Wedlake Bell advises the shareholders of Katalyst Diagnostics on the sale of Katalyst to Cruinn Diagnostics
Wedlake Bell has advised the shareholders of Katalyst Diagnostics, the market leader in the provision of premium and cutting edge POCT diagnostic solutions on the sale of the entire issued share capital to Cruinn Diagnostics.
Katalyst Diagnostics is a UK-based point-of-care diagnostics business specialising in premium and innovative diagnostic solutions for healthcare organizations and clinical professionals, providing access to advanced point-of-care technologies in areas including haematology, clinical chemistry and antipsychotic drug monitoring. Katalyst Diagnostics supports NHS and other healthcare organisations across the UK and Ireland, with solutions designed to deliver rapid, laboratory-quality results at the point of care. Its portfolio includes HemoScreen, Piccolo Xpress and MyCare INSITE, supported by specialist expertise in diagnostics, training, logistics and customer service.
Cruinn Diagnostics is one of Ireland’s leading laboratory and diagnostic distributors, supplying clinical diagnostics, laboratory equipment and consumables, life sciences, pharmaceutical and food testing solutions, point-of-care diagnostics, ultrasound systems and calibration and testing services to hospitals, independent laboratories, pharmaceutical and life sciences companies, universities, research organisations and other specialist customers across Ireland.
The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland.
Afsheen Khan, the Chief Commercial Officer of Katalyst Diagnostics, said: “From the outset, Wedlake Bell were supportive, responsive, proactive and technically excellent offering practical solutions throughout the process. We valued the support of the team throughout the process, led by Adam Lynch and including James French, Enea Aniaj and Ben Holmes, and were delighted to have them as our trusted advisers on this transaction, helping us achieve a successful outcome.”
Adam Lynch, Corporate Partner at Wedlake Bell, commented: “We were pleased to have supported the shareholders of Katalyst Diagnostics on this successful transaction. Katalyst Diagnostics has built an impressive reputation in the point-of-care diagnostics sector through its strong customer relationships and specialist expertise. The combination with Cruinn Diagnostics creates a compelling platform for future growth and innovation, and we wish both businesses every success as they begin this next chapter together.”
Wedlake Bell’s M&A team was led by Adam Lynch (Partner, Head of Corporate), with support from James French (Senior Associate, Corporate), Enea Aniaj (Solicitor, Corporate) and Ben Holmes (Solicitor, Corporate). Specialist support was provided by Mike Ridsdale (Partner) and Lucy Foster (Solicitor) on corporate tax matters and Choy Lau (Legal Director) on employment matters.
Corporate Finance advice was provided by Oaklins S&W and led by Ben Laing.
Meet the team:
Enea Aniaj
- Solicitor
- Corporate
